Jamjoom Pharmaceuticals Factory Company SJSC (4015)

Currency in SAR
176.70
-0.30(-0.17%)
Closed·

4015 Financial Summary

Key Ratios

P/E Ratio30.07
Price/Book7.98
Debt / Equity0.16%
Return on Equity27.3%
Dividend Yield2.58%
EBITDA424.44M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of SAR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.87%
Dividend Yield
2.58%
Industry Median 1.65%
Annualised payout
4.56
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

2 Buy
4 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 178.20
(+0.85% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
2.24 / --
Revenue / Forecast
458.00M / --
EPS Revisions
Last 90 days

FAQ

What were Jamjoom Pharmaceuticals Factory's earnings for the latest quarter?

The Jamjoom Pharmaceuticals Factory EPS (TTM) is 5.87. Jamjoom Pharmaceuticals Factory reported sales of 457.53, net income of 157.03, and EPS of 2.24 for the latest quarter.

What was Jamjoom Pharmaceuticals Factory's net income for the latest quarter?

Jamjoom Pharmaceuticals Factory's net income for the latest quarter was 157.03.

How did Jamjoom Pharmaceuticals Factory's performance compare year-over-year in the latest quarter?

The company's revenue moved from 259.70 in the previous quarter to 457.53 in the latest quarter, and net income moved from 51.61 to 157.03 compared to the previous quarter.

What is Jamjoom Pharmaceuticals Factory's net profit margin on a TTM basis?

Jamjoom Pharmaceuticals Factory's trailing twelve months (TTM) net profit margin is 27.04%.

How does Jamjoom Pharmaceuticals Factory's debt to equity ratio compare to industry standards?

Jamjoom Pharmaceuticals Factory's total debt-to-equity ratio is 0.16%.

What is Jamjoom Pharmaceuticals Factory's return on investment on a TTM basis?

Jamjoom Pharmaceuticals Factory's trailing twelve months (TTM) return on investment (ROI) is 27.30%.

Did Jamjoom Pharmaceuticals Factory gain or lose cash last quarter?

In the latest quarter, Jamjoom Pharmaceuticals Factory's net change in cash was -124.21 million.

What were Jamjoom Pharmaceuticals Factory's total assets and liabilities in the latest quarter?

As of the latest quarter, Jamjoom Pharmaceuticals Factory reported total assets of 1,904.53 million and total liabilities of 268.89 million.

How has Jamjoom Pharmaceuticals Factory's total revenue grown this year?

Jamjoom Pharmaceuticals Factory's total revenue was 259.70 in the previous quarter and 457.53 in the latest quarter.

What is Jamjoom Pharmaceuticals Factory's gross margin on a TTM basis?

Jamjoom Pharmaceuticals Factory's trailing twelve months (TTM) gross margin is 61.96%.

What was Jamjoom Pharmaceuticals Factory's revenue per share for the latest quarter?

Jamjoom Pharmaceuticals Factory's revenue per share for the latest quarter was 23.45.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.